Kazuya Toriumi1,2, Mika Oki1, Eriko Muto1, Junko Tanaka1, Akihiro Mouri1,3,4, Takayoshi Mamiya1,4, Hyoung-Chun Kim5, Toshitaka Nabeshima6,7,8. 1. Department of Chemical Pharmacology, Meijo University, Nagoya, Japan. 2. Project for Schizophrenia Research, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. 3. Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, Nagoya, Japan. 4. Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan. 5. Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Korea Institute of Drug Abuse, Chunchon, South Korea. 6. Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan. tnabeshi@ccalumni.meijo-u.ac.jp. 7. Nabeshima Laboratory, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tenpaku-ku, Nagoya, 468-8503, Japan. tnabeshi@ccalumni.meijo-u.ac.jp. 8. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan. tnabeshi@ccalumni.meijo-u.ac.jp.
Abstract
RATIONALE: We previously reported that prenatal treatment with phencyclidine (PCP) induces glutamatergic dysfunction in the prefrontal cortex (PFC), leading to schizophrenia-like behavioral deficits in adult mice. However, little is known about the prenatal effect of PCP treatment on other types of neurons. OBJECTIVES: We focused on γ-aminobutyric acid (GABA)-ergic interneurons and evaluated the effect of prenatal PCP exposure on the neurodevelopment of GABAergic interneurons in the PFC. METHODS: PCP was administered at the dose of 10 mg/kg/day to pregnant dams from embryonic day 6.5 to 18.5. After the pups were reared to adult, we analyzed their GABAergic system in the PFC using immunohistological, biochemical, and behavioral analyses in adulthood. RESULTS: The prenatal PCP treatment decreased the density of parvalbumin-positive cells and reduced the expression level of glutamic acid decarboxylase 67 (GAD67) and GABA content of the PFC in adults. Additionally, prenatal PCP treatment induced behavioral deficits in adult mice, such as hypersensitivity to PCP and prepulse inhibition (PPI) deficits. These behavioral deficits were ameliorated by pretreatment with the GABAB receptor agonist baclofen. Furthermore, the density of c-Fos-positive cells was decreased after the PPI test in the PFC of mice treated with PCP prenatally, and this effect was ameliorated by pretreatment with baclofen. CONCLUSIONS: These findings suggest that prenatal treatment with PCP induced GABAergic dysfunction in the PFC, which caused behavioral deficits.
RATIONALE: We previously reported that prenatal treatment with phencyclidine (PCP) induces glutamatergic dysfunction in the prefrontal cortex (PFC), leading to schizophrenia-like behavioral deficits in adult mice. However, little is known about the prenatal effect of PCP treatment on other types of neurons. OBJECTIVES: We focused on γ-aminobutyric acid (GABA)-ergic interneurons and evaluated the effect of prenatal PCP exposure on the neurodevelopment of GABAergic interneurons in the PFC. METHODS:PCP was administered at the dose of 10 mg/kg/day to pregnant dams from embryonic day 6.5 to 18.5. After the pups were reared to adult, we analyzed their GABAergic system in the PFC using immunohistological, biochemical, and behavioral analyses in adulthood. RESULTS: The prenatal PCP treatment decreased the density of parvalbumin-positive cells and reduced the expression level of glutamic acid decarboxylase 67 (GAD67) and GABA content of the PFC in adults. Additionally, prenatal PCP treatment induced behavioral deficits in adult mice, such as hypersensitivity to PCP and prepulse inhibition (PPI) deficits. These behavioral deficits were ameliorated by pretreatment with the GABAB receptor agonist baclofen. Furthermore, the density of c-Fos-positive cells was decreased after the PPI test in the PFC of mice treated with PCP prenatally, and this effect was ameliorated by pretreatment with baclofen. CONCLUSIONS: These findings suggest that prenatal treatment with PCP induced GABAergic dysfunction in the PFC, which caused behavioral deficits.
Authors: C E Marx; D W Bradford; R M Hamer; J C Naylor; T B Allen; J A Lieberman; J L Strauss; J D Kilts Journal: Neuroscience Date: 2011-07-01 Impact factor: 3.590
Authors: Gregory C Carlson; Konrad Talbot; Tobias B Halene; Michael J Gandal; Hala A Kazi; Laura Schlosser; Quan H Phung; Raquel E Gur; Steven E Arnold; Steven J Siegel Journal: Proc Natl Acad Sci U S A Date: 2011-10-03 Impact factor: 11.205
Authors: Jenny L Wiley; Katriona G Bühler; Kari L Lavecchia; Kenneth M Johnson Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2003-08 Impact factor: 5.067
Authors: Yingwei Mao; Xuecai Ge; Christopher L Frank; Jon M Madison; Angela N Koehler; Mary Kathryn Doud; Carlos Tassa; Erin M Berry; Takahiro Soda; Karun K Singh; Travis Biechele; Tracey L Petryshen; Randall T Moon; Stephen J Haggarty; Li-Huei Tsai Journal: Cell Date: 2009-03-20 Impact factor: 41.582
Authors: M J Gandal; J Sisti; K Klook; P I Ortinski; V Leitman; Y Liang; T Thieu; R Anderson; R C Pierce; G Jonak; R E Gur; G Carlson; S J Siegel Journal: Transl Psychiatry Date: 2012-07-17 Impact factor: 6.222
Authors: Carles Tapias-Espinosa; Cristóbal Río-Álamos; Ana Sánchez-González; Ignasi Oliveras; Daniel Sampedro-Viana; Maria Del Mar Castillo-Ruiz; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel Journal: Neuropsychopharmacology Date: 2019-04-16 Impact factor: 7.853
Authors: Stefano Calovi; Paula Mut-Arbona; Pál Tod; András Iring; Annette Nicke; Susana Mato; E Sylvester Vizi; Jan Tønnesen; Beata Sperlagh Journal: Front Mol Neurosci Date: 2020-11-11 Impact factor: 5.639
Authors: Jose Antonio Garcia-Partida; Sonia Torres-Sanchez; Karina MacDowell; Maria Teresa Fernández-Ponce; Lourdes Casas; Casimiro Mantell; María Luisa Soto-Montenegro; Diego Romero-Miguel; Nicolás Lamanna-Rama; Juan Carlos Leza; Manuel Desco; Esther Berrocoso Journal: Front Pharmacol Date: 2022-07-26 Impact factor: 5.988